TERNS PHARMACEUTICALS INC's ticker is TERN and the CUSIP is 880881107. A total of 104 filers reported holding TERNS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 4.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $138,325 | -68.8% | 27,500 | -45.8% | 0.00% | -72.7% |
| Q2 2023 | $443,625 | -26.1% | 50,700 | 0.0% | 0.01% | -31.2% |
| Q1 2023 | $600,288 | -36.4% | 50,700 | -45.3% | 0.02% | -33.3% |
| Q4 2022 | $943,686 | +130.7% | 92,700 | +33.4% | 0.02% | +118.2% |
| Q3 2022 | $409,000 | +261.9% | 69,500 | +52.7% | 0.01% | +266.7% |
| Q2 2022 | $113,000 | -39.2% | 45,500 | -27.4% | 0.00% | -25.0% |
| Q1 2022 | $186,000 | -72.4% | 62,700 | -34.3% | 0.00% | -69.2% |
| Q4 2021 | $675,000 | – | 95,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,099,309 | $13,015,819 | 9.59% |
| VR Adviser, LLC | 3,619,522 | $42,855,140 | 8.37% |
| Vivo Capital, LLC | 6,657,992 | $78,830,625 | 5.47% |
| Fairmount Funds Management LLC | 2,040,000 | $24,153,600 | 4.15% |
| Decheng Capital Management III (Cayman), LLC | 714,285 | $8,457,134 | 3.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 667,922 | $7,908,196 | 3.26% |
| Ikarian Capital, LLC | 721,341 | $8,540,677 | 1.94% |
| Orbimed Advisors | 7,619,135 | $90,210,558 | 1.77% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,448,275 | $40,827,576 | 1.72% |
| CROSSPOINT FINANCIAL, LLC | 12,054 | $142,719 | 1.54% |